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ABSTRACT 
The Lewis x (Lex) structure (Galβ1–4(Fucα1–3)GlcNAc-R) is a carbohydrate epitope 
comprising the stage-specific embryonic antigen-1 (SSEA-1) and CD15, and it is 
synthesized by α1,3-fucosyltransferase 9 (Fut9). Fut9 is expressed specifically in the 
stomach, kidney, brain, and in leukocytes, suggesting a specific function in these tissues. 
In this study, the N-linked glycan mass spectrometry profile of wild-type mouse kidney 
glycoproteins revealed the presence of abundant terminal fucoses, which were lost 
following knockout of the Fut9 gene; the terminal fucose was therefore concluded to be 
Lex. These results suggested that Lex presence is widespread rather than being limited to 
specific proteins. We endeavored to comprehensively identify the Lex carriers in the 
mouse kidney. Glycopeptides carrying fucosylated glycans were collected by Aleuria 
aurantia lectin (AAL) affinity chromatography from kidney homogenates of wild-type 
and Fut9 knockout mice. The site-specific N-glycomes on the glycopeptides were 
subsequently analyzed by adopting a new glycoproteomic technology composed of 
dissociation-independent assignment of glycopeptide signals and accurate mass-based 
prediction of the N-glycome on the glycopeptides. Our analyses demonstrated that 
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24/32 glycoproteins contained the Lex N-glycan structure in wild-type kidney; of these, 
Lex was lost from 21 in the knockout mice. This is the first report of large-scale 
identification of Lex-carrying glycoproteins from a native sample based on the 
site-specific glycome analysis. 
 
KEYWORDS: α1,3-fucosyltransferase 9 (Fut9), knockout mouse, kidney, Lewis x, 
glycoproteomics, IGOT-LC–MS, site-specific N-glycome analysis 
 
 
 
 
 
 
 
 
 
 4 
INTRODUCTION 
  Lewis x (Lex) is an epitope of stage specific embryonic antigen-1 (SSEA-1) and is 
known as a neural stem cell marker.1 Early embryos of mice from the eight-cell to the 
morula stage develop SSEA-1,2 and it is thought that this antigen may be essential to the 
initial embryonic cell compaction in mice, as proposed by Solter. An in vitro 
fucosyltransferase assay suggested that the Fut4 and Fut9 gene products control 
biosynthesis of the Lex structure in mice.3, 4 However, Fut9 has a higher ability to 
transfer fucose and synthesize Lex on a nonreducing end than does Fut4,3 whereas Fut4 
has strong activity for fucose transfer and Lex synthesis at a reducing end.1 From 
various observations and reports, we estimated that Lex is synthesized primarily by Fut9 
in vivo.3–7 
  To determine the function of Fut9 in vivo, Kudo et al. generated knockout mice (KO 
mice).8 The KO mice had the ability to reproduce and grow normally. The Lex epitope 
of SSEA-1 was completely absent in early embryos and primordial germ cells in the KO 
mice, although the Fut4 gene was expressed.8 However, as the KO mice lacking the Lex 
epitope of SSEA-1 developed normally, the hypothesis with respect to its significance 
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during embryogenesis was incorrect.8 
  The Fut9 gene is expressed in the stomach, kidney, brain, and certain other tissues in 
normal wild-type (WT) mice.9–11 The Fut9 protein can produce a Lex epitope on both 
glycoproteins and glycolipids. For example, Lex structure is an epitope of the CD15 
antigen on both glycoprotein and glycolipid. Neurobiologists have suggested that the 
CD15 antigen is important for synaptogenesis during brain development.12–14 In 
concordance with this, it has recently been shown that Fut9 is one of the causative 
genes of schizophrenia.15 In addition, it has been predicted that CD15 might be involved 
in neutrophilic function, intracellular interactions, phagocytosis, and the stimulation of 
degranulation, as well as in respiratory bursts.16, 17 
  Lex and Fut9 protein are colocalized in neurons,4 subglandular epithelial cells in the 
stomach5, the proximal tubules in kidney,18 and mature polymorphs.19 This strongly 
indicates that Fut9 is responsible for Lex synthesis in vivo. The expression of Fut9 is 
closely regulated by both cell- and stage-specific mechanisms. However, the function of 
Lex in this process has not been determined, and little is known regarding the details of 
its biological function in other cells, as very few proteins modified by Lex have been 
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identified. To elucidate the function of Lex, it is important to identify the core proteins 
carrying Lex.  
  It is theoretically possible to use an antibody such as anti-SSEA-1 for capturing 
proteins carrying Lex. We examined several anti-Lex antibodies; however, we could not 
find the antibody applicable to capturing Lex-carrying glycopeptides comprehensively 
(data not shown). Thus, we designed a new approach to comprehensively identify 
Lex-carrying glycoproteins. In this study, we identified glycopeptides carrying fucose(s) 
from normal mouse kidney using isotope-coded glycosylation site-specific tagging 
(IGOT),20 and we specified Lex-carrying glycopeptides among them by analyzing 
site-specific glycome using the newly developed N-glycoproteomics technology. 
Consequently, we revealed glycoproteins from which Lex was lost in Fut9 KO mice 
compared to WT to determine the set of Lex-carrying glycoproteins (Fut9 target 
proteins). 
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EXPERIMENTAL SECTION  
  Knockout Mice. Fut9 KO mice generated as previously described using standard 
gene-targeting techniques were backcrossed for five generations into the C57BL/6 
genetic background.8 Experimental animals were bred and housed in a specific 
pathogen-free animal facility and provided with sterilized chow and water ad libitum. 
The Institutional Animal Care and Use Committee approved the use of animals in this 
study. 
  Preparation of Mouse Kidney Glycopeptides. Male mice (60 or 64 weeks old) 
were anesthetized by 2-propanol inhalation. The blood was removed from an incision 
on the right atrium and was replaced by phosphate-buffered saline (PBS) into the left 
ventricle, followed by removal of the kidneys and storage at –80°C. Peptide preparation 
was carried out as previously described.21, 22 Briefly, four kidneys from two mice (total 
weight: 1.06 g for WT mice and 1.02 g for KO mice) were homogenized using a 
polytron with a denaturing buffer (0.5 M Tris-HCl, pH 8.5, containing 7 M 
guanidine-HCl and 50 mM EDTA) and the supernatant was collected. The kidney 
homogenates were reduced with DTT and then S-alkylated with iodoacetamide, 
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followed by dialysis. An aliquot of the protein preparation was digested with lysyl 
endopeptidase (Wako) and N-tosylphenylalanyl chloromethyl ketone (TPCK)-treated 
trypsin (Thermo Scientific). An aliquot of the digested protein was subjected to 
hydrophilic interaction chromatography (HILIC) on an Amide-80 column to collect 
glycopeptides. 20, 21 The bound fraction was evaporated to remove MeCN. 
  Collection of Glycopeptides Carrying Fucosylated Glycans by Aleuria aurantia 
lectin (AAL)-Affinity Chromatography. An aliquot of the glycopeptide fraction was 
diluted with 10 mM Tris-HCl, pH 7.5 and applied to an AAL-immobilized column (5 
mm i.d. × 50 mm, J-Oil Mills). After washing, the glycopeptides were eluted with 5 
mM L-(–)-Fucose. To achieve maximal recovery, the flow-through fraction was 
reloaded onto the same column four times. The recovery rate was not increased during 
the fourth application. The bound fractions were combined and cleaned by reversed 
-phase chromatography on a Mightysil RP-18GP column (2 mm i.d. × 50 mm, Kanto 
Chemical Co., Inc.).  
  Deglycosylation and IGOT of N-Glycopeptides. AAL-bound (AAL(+)) 
N-glycopeptides were treated with peptide-N-glycosidase F (PNGase, Takara-Bio) in 
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18O-labeled water to remove glycan moieties and to concomitantly label glycosylated 
Asn residues with the stable isotope as described previously.20 This step is called IGOT. 
  Liquid Chromatography-Mass Spectrometry (LC–MS) Identification of AAL(+) 
Glycopeptides. The 18O-labeled glycopeptides were analyzed by a nanoflow LC–MS 
system as described previously.22 Briefly, the IGOT-peptides were separated by the LC 
system using a reverse phase tip column (150 µm i.d. × 75 mm, C18S, Nikkyo Technos), 
and the eluted peptides were electrosprayed directly into the LTQ-Orbitrap Velos mass 
spectrometer (Thermo Scientific). The mass spectrometer was operated in the positive 
ion mode employing a data-dependent method. Full MS scans were acquired by the 
Orbitrap analyzer with a resolution of 30000 at m/z 400 in the mass range of m/z 440–
1500. The 10 most intense ions were fragmented in a data-dependent mode by 
collision-induced dissociation (CID) with a normalized collision energy of 35, 
activation q = 0.25, activation time of 10 ms, and one microscan, and analyzed in the 
ion trap MS. The following conditions were used: spray voltage, 2.0 kV; ion transfer 
tube temperature, 250°C; ion selection threshold for MS/MS, 10000 counts; maximum 
ion accumulation times, 500 ms for full scans; and dynamic exclusion duration, 60 s (10 
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ppm window; maximum number of excluded peaks, 500). 
  Proteins were identified by Mascot database search as described previously.23 Briefly, 
raw data files were converted to Mascot generic format files using Protein Discoverer 
software version 1.4 (Thermo Fisher Scientific) and then processed using the Mascot 
server version 2.4 (Matrix Science) to assign peptides by searching the NCBI mouse 
RefSeq protein sequence database (30427 entries, downloaded on December 13, 2011). 
The database-search was performed using the parameters described as follows: fixed 
modification, carbamoylmethylation (Cys); variable modifications, pyro-Glu (Gln at 
peptide N-terminus), oxidation (Met), and deamidation with 18O (Asn, +2.98826 Da); 
enzyme, trypsin, and LEP; maximum number of missed cleavages, 2; peptide molecular 
weight tolerance, 7 ppm; peptide charges, +2 to +4; MS/MS tolerances, 0.8 Da; 
significance threshold, 0.05. False discovery rate, < 0.02. Peptide search results were 
exported as a CSV file and processed by Microsoft Excel. At first, we selected the 
peptides with rank 1 and expectation value within 0.05 as “identified peptides.” If a 
prospective “identified peptide” contained one or more 18O-labeled aspartic acid 
residues in the consensus tripeptide sequence for N-glycosylation 
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(Asn-Xaa-[Ser/Thr/Cys], where Xaa is any amino acid except Pro), the peptide was 
accepted as an “N-glycopeptide.” 
  MS Analysis of the N-Glycans Released from Glycopeptides. Two fractions of 
glycopeptides were collected to compare their N-glycomes by MS, that is, (1) whole 
glycopeptides collected with an Amide-80 column (Amide(+) glycopeptides) and (2) 
AAL(+) glycopeptides from WT and KO mice. Release and derivatization of N-glycans 
were performed according to the method as reported previously with slight 
modifications.24 Briefly, the glycopeptides were treated with PNGase and applied to an 
OASIS HLB cartridge (Waters). The pass fractions were recovered, and permethylated 
with methyl iodide. The glycans were collected with a Sep-Pak C18 cartridge (Waters), 
eluted with 95% MeCN, and lyophilized. 
  A matrix (2,5-dihydroxybenzoic acid (DHB) (proteomics grade; Wako), 10 mg/mL 
DHB in 30% ethanol, 0.5 µL) was fixed onto a stainless sample plate for matrix assisted 
laser desorption/ionization (MALDI)-MS (MTP 384 target plate ground steel BC) 
(Bruker Daltonics). Then, the sample of permethylated N-glycans dissolved with MeCN 
was spotted onto the dried matrix (DHB). The mass spectrum was obtained by 
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MALDI-MS (Ultraflex TOF/TOF, Bruker Daltonics) in reflectron positive ion mode. 
The sample was ionized by nitrogen laser (337 nm, 7 Hz). The ions were accelerated at 
20 kV with 400 ns delayed extraction. The spectrum was analyzed using flexAnalysis 
software (ver. 2.0, Bruker Daltonics). The CID-MS/MS spectra were obtained using 
MALDI-QIT-TOF MS (AXIMA-QIT, Shimadzu-Biotech) using Shimadzu Biotech 
Launchpad software (ver. 2.8.5, Shimadzu-Biotech). A nitrogen laser (337 nm, 5 Hz) 
was used for sample ionization. The DHB was used as a matrix, and it was mixed with 
the sample as described above. In CID-MS/MS analysis, the CID energy was controlled 
so that the signal of the precursor ion almost disappeared. Argon was used as a collision 
gas. 
  Site-Specific N-Glycome Analysis of AAL(+) Glycopeptides.  
(1) Assignment of MS Glycopeptide Signals. Accurate masses of AAL(+) 
glycopeptides were obtained by LC–MS analysis using an LTQ-Orbitrap mass 
spectrometer (Thermo Scientific). To maximize the mass accuracy, masses were 
measured by an Orbitrap analyzer (positive ion mode) at a resolution of 100000, and 
with mass locking at 445.12003 for polysiloxane. Simultaneously, MS/MS spectra were 
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acquired in a data-dependent manner for the two most intense signals by the 
high-energy collision-induced dissociation (HCD) method (collision energy: 50) using 
Orbitrap. All MS1 signals with intensities 50000 or higher were filtered from the 
complete raw data obtained; the list was composed of m/z, intensity, scan number, and 
retention time for each signal. Among these, the signal peaks were selected by the 
following data processing steps using an in-house software program: (1) the peaks of 
each signal that had the highest intensities, along with the scans (retention time), were 
selected within a specified mass range, e.g., 0.025; (2) the valence of the ion peaks was 
determined to assign a monoisotope mass value of each peak; and (3) the ion peaks of 
glycopeptides which had common peptides but different glycans, were selected as a 
cluster according to the following conditions. First, a pair of glycopeptide peaks must 
had a close retention time, e.g., within 0.4 min (24 s), and the mass difference between 
them needed to correspond to the mass of one of the specified monosaccharides, e.g., 
Hex (mannose, galactose, and glucose), HexNAc (GlcNAc and GalNAc), dHex (fucose), 
or optionally LacNAc, with an error of 10 ppm. Then, the pairing was extended to form 
a cluster of glycopeptides; that is, a pair of peaks A and B and a pair of peaks B and C 
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were connected as a cluster of peaks A, B, and C. To eliminate false assignment by 
accidental coincidence, the minimum number of members in a cluster was set to 4. At 
this stage, a number of glycopeptide clusters could be found even without use of 
MS/MS spectra. 
(2) Prediction of the Core Peptide and Glycan Compositions for Each Glycopeptide 
Cluster. Plausible combinations of a core peptide and glycan compositions of each 
glycopeptide cluster were predicted using the following simple equation and a set of 
three mass lists using in-house software: (1) the observed masses of glycopeptides, 
which were found by the above method as clusters; (2) the theoretical masses of core 
peptide candidates, which were calculated from the amino acid sequences and 
modifications of glycopeptides identified by IGOT-LC–MS analyses; and (3) the 
masses of the monosaccharides (Hex, HexNAc, dHex, and optionally LacNAc). 
Mglycopeptide 
= Mpeptide + Mhex*X + Mhexnac*Y + Mdhex*Z 
= Mglycopeptide +/– error 
An error of ± 10 ppm was allowed for matching. The ranges of numbers for Hex, 
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HexNAc, and dHex were set to 3–8, 2–8, and 0–4, respectively. Single or multiple 
combinations of specific peptides with various glycan compositions (X, Y, and Z) were 
listed for each glycopeptide cluster. 
(3) Confirmation of the Predicted Core peptide and the Site-Specific Glycome. To 
confirm the core predictions, first, the glycome assigned to a cluster was evaluated. The 
N-glycome profile of the whole sample of AAL(+) glycopeptides was obtained by 
MALDI-MS as described above. Major glycan compositions were listed as a table. If a 
predicted glycan composition coincided with any one of the listed glycomes, the 
predicted combination was marked in the prediction results table. The core peptides that 
got the most marks in a cluster were regarded as the primary candidates of that cluster. 
Then, the peptide sequences of the primary candidates were inspected manually for the 
HCD-MS/MS spectrum of the representative glycopeptide(s) of the cluster. If the partial 
sequence recognized was not coincident with that of the primary candidate, other 
candidate sequences in the same cluster were checked. If the sequence did not 
correspond to any one of the predicted candidate peptides, the sequence was searched 
against the protein sequence database using a BLAST search. After identification of 
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peptides, the glycome on the searched peptide was calculated. In the case in which the 
reassigned glycome was considerably different from the whole glycome, the assignment 
was discarded. 
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RESULTS 
  Fut9 is strongly expressed in the kidney, brain, and stomach.9 We used the kidneys to 
identify Lex carrier proteins. A schematic of the procedure used to identify 
glycoproteins carrying Lex is shown in Figure 1. The glycopeptides from 
trypsin-digested mouse kidneys were prepared by HILIC on an Amide80 column. An 
aliquot of this glycopeptide eluate was treated by PNGase and analyzed for isolated 
N-glycan structures by MALDI-MS. The remaining glycopeptides were applied to an 
AAL column to capture fucosylated glycopeptides. Then, the core peptides from the 
AAL(+) glycopeptide pool were identified by IGOT processing by PNGase digestion, 
and the isolated N-glycans were analyzed to profile the fucosylated glycans. To identify 
the glycoproteins which possessed Lewis type glycans, we analyzed the AAL(+) 
glycopeptides by LC–MS, made a list of glycopeptide clusters using site-specific 
glycome analysis, and by matching the information provided by the IGOT method, 
identified the glycan profile of individual glycopeptides and identified the carrier 
proteins of Lex. 
  Profiling the N-glycan Structures in the Kidneys of WT and KO Mice. The 
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profiles of the N-glycans on mouse kidney glycoproteins were obtained by MS analysis 
(Figure 2, Supplementary Table 1a, b). In the figure, the assigned glycan compositions 
are indicated by digits, presented as XYZ, which represent the numbers of hexose (Hex), 
N-acetylhexosamine (HexNAc), and deoxyhexose (dHex) monosaccharides after 
eliminating those of the trimannosyl core. If sialic acids (Neu5Ac and Neu5Gc) were 
identified, these were added and indicated as Ac and Gc, respectively. For example, the 
glycan composition of the biggest signal in Figure 2a (signal 233) indicates 
Hex2HexNAc3dHex3. Incorporation of sialic acid can be seen, for example, in 221-Ac1, 
which is common in both Figure 2a, b. 
  The profile of WT mice showed N-glycans having multiple fucoses in addition to 
high-mannose glycans (Figure 2a). The glycan composition suggested that most of the 
N-glycans had bisecting GlcNAc and multiple fucoses (Figure 2). This spectrum agreed 
well with the data available at the Consortium for Functional Glycomics (CFG) 
homepage (http://www.functionalglycomics.org/fg/). The existence of multiple dHex 
molecules showed the existence of at least one fucose on the nonreducing end of the 
glycan, but it could not discriminate whether this structure was Lex or Lewis a (Lea), or 
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another structure from the composition. However, because the mouse cannot synthesize 
Lea, these fucoses were presumed to be Lex. On the other hand, examination of the 
N-glycans of the KO mice showed that the N-glycans having multiple fucoses in WT 
resulted in those having a single fucose in KO mice. This change arising from KO of 
the Fut9 gene suggested that one of the multiple fucoses of the WT was a core fucose, 
and that the others were terminal fucoses, which could be presumed to be Lex. This is 
strongly supported by the data that mouse kidney does not express α1,2 
fucosyltranseferases which are responsible for the synthesis of Fucα1,2 Gal epitope as 
reported in the BioGPS database, http://biogps.org/#goto=welcome, although Fut9 is 
abundantly expressed. From the CFG database, it is recognized that almost all complex 
type N-glycans have core fucose. The fact that most of the complexed glycans had 
multiple fucoses suggested that Lex existed on proteins globally rather than being 
limited to specific proteins. In contrast, in the KO mice, the disappearance of terminal 
fucoses was accompanied by an increase of sialic acids, which were primarily Neu5Gc. 
  Identification of AAL(+) Glycopeptides and Their N-glycan Profiles. In general, 
to identify glycoproteins carrying a specific glycan motif, methods to enrich such 
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glycopeptides using a specific lectin and antibodies are utilized. However, there is no 
known method to enrich glycopeptides carrying Lex. Currently, there is no known lectin 
that specifically binds to Lex. From the results of the structural analysis of kidney 
N-glycans in this study, core fucosylation was found to occur comprehensively on the 
complex type N-glycans. This result accords with the data shown in the CFG database. 
Therefore, we used AAL to comprehensively capture complex type N-glycopeptides, 
and we analyzed the site-specific glycome to identify Lex-carriers. Because this analysis 
provides not only a list of Lex-carriers but also the information on glycan alteration 
status, we selected AAL for comprehensive capturing rather than for specific capturing 
of Lex-carriers. To attempt this, we enriched fucosylated glycopeptides using an AAL 
column and identified Lewis-carrying glycopeptides by confirming their glycan 
compositions. Accordingly, Amide(+) glycopeptides from the kidneys of WT and KO 
mice were applied to AAL columns and fucose-carrier glycopeptides were collected. A 
fraction of the AAL(+) glycopeptides was analyzed by IGOT and the core peptides 
were identified by LC–MS analysis (Table 1, Supplementary Table 2). Almost the same 
numbers of fucosylated glycopeptides were recovered from both WT and KO mice by 
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AAL capturing. For WT mice, 831 glycoproteins composed of 2311 glycopeptides were 
identified by the two analyses. Similarly, for KO mice, 856 glycoproteins composed of 
2220 glycopeptides were identified. Of these, 1762 glycopeptides were identified as 
common between WT and KO mice, and 549 and 458 glycopeptides were identified 
only from WT or KO mice, respectively. In total, 2769 glycopeptides were identified. 
The bracketed numbers in Table 1 present the number of nonredundant N-glycosylated 
peptides. The information from these peptides was compiled as the basic data that was 
used in the subsequent site-specific glycome analysis. 
  N-glycans were isolated from the AAL(+) fraction by PNGase treatment and 
analyzed by MS after permethylation (Figure 3, Supplementary Table 3a, b). In WT 
mice, all N-glycans contained dHex (fucose), which indicated that the AAL capture was 
specific to fucosylated glycans (Figure 3a). The main N-glycan structures from WT 
kidneys were bisecting-GlcNAc bound to biantennary and triantennary glycans, and 
fucoses connected to chitobiose-GlcNAc and to a nonreducing end. The degree of 
fucosylated peptides was high overall, and a trace amount of sialic acids was also 
detected. On the other hand, only one fucose was found exclusively in kidneys from KO 
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mice (Figure 3b). Because all of the terminal fucoses were absent in the KO mice 
profile, we concluded that the terminal fucose detected in WT kidneys constituted Lex. 
In addition, from the MS/MS analysis of the major N-glycans, it was confirmed that the 
remaining fucose in the KO mice was the core fucose (Figure 4a, b, Supplementary 
Table 4). Subsequently, we compared the N-glycans having the same glycan structures 
except for a fucose between the WT and KO mice. MS/MS analysis was applied to 
signals 2459.5 (WT) and 2284.9 (KO), which shared Hex1HexNAc3 in common 
(Figure 4a), and to signals 2838.0 (WT) and 2488.9 (KO), having Hex2HexNAc3 in 
common (Figure 4b). The enlarged picture (circled) in the lower left shows that signal 
660.4, a Lewis-type glycan composed of three monosaccharides observed in WT mice, 
was not present in the KO profile. The remaining single fucose was linked to the 
innermost GlcNAc of chitobiose as a core fucose from these signals (Figure 4b). 
  Identification of the Carrier Proteins of Lex by Site-Specific Glycome Analysis. 
CID-MSn , HCD-MS/MS, and electron transfer dissociation (ETD)/ electron capture 
dissociation (ECD)-MS/MS methods are available to analyze and identify both the 
peptide moieties and glycan compositions of glycopeptides.25-28 However, analyses of 
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the fragment ions generated by the dissociations and the structural identification of both 
glycans and peptides depend upon complicated manual analysis and cause a low cover 
rate due to an elevation of the detection limit. Therefore, we devised a method to sort 
the glycopeptide signals as clusters based on the chromatographic behavior of the 
glycopeptides and the heterogeneity of glycans. Furthermore, we developed software 
that could estimate the glycan composition from the differences between the theoretical 
mass of the existing glycopeptide core and the accurate measured glycopeptide mass, 
and we utilized this to analyze the site-specific glycome. We note that this analysis was 
performed on glycopeptide samples in which sialic acid had been removed. 
  The desialylated AAL(+) glycopeptides of WT and KO mouse kidneys were 
analyzed by data-dependent LC–MS/MS method: MS was measured by Orbitrap 
analyzer. The peaks of the peptide signals were extracted from the survey MS1 data 
(Figure 5a, c). The glycopeptide clusters were searched against the extracted MS data 
using in-house software in which the number of minimum cluster members was set to 4 
(Figure 5b, d). Accordingly, 103 and 141 glycopeptide clusters were assigned for the 
WT and KO samples, respectively (Figure 6a). The mass of the glycopeptides and the 
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mass of the core peptides identified previously by IGOT were compared 
comprehensively using the in-house software. Based on the predicted results, each core 
peptide and its glycome were confirmed by MS/MS analysis (Supplementary Figure 1). 
Finally, 72 and 99 clusters comprised of total 522 and 591 signals were identified for 
the WT and KO samples, respectively (Figure 6a, Supplementary Table 5). For the WT 
data, 72 clusters were assigned to 51 sites, and 42 out of 51 (82%) sites contained 
glycopeptides having multiple fucoses in a cluster (Figure 6b), and 24 glycoproteins 
were identified as Lex carriers (Figure 6c). In contrast, for the KOs, only two out of 99 
clusters (one of 70 sites), i.e. one protein, carried the Lex structure, meaning that Lex 
modifications were generally absent in this sample. 
  In the WT sample, 24 of the 32 glycoproteins (75%) were identified as Lex carriers, 
suggesting that Lex presence is widespread rather than being limited to specific proteins. 
In the site-specific glycome data, 35 sites overlapped, and in the 28/35 sites, it was 
confirmed that the 28 sites contained Lex, but their Lex were disappeared by Fut9 KO 
(Figure 6b). As shown in the representative data (Figure 7), the N-glycomes containing 
multiple fucoses in the WT sample were completely absent from the KOs, which agrees 
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with the result of the N-glycome isolated from the AAL(+) fraction, wherein no changes 
in the profile of glycan structures were observed except for a decrease of fucose (e.g., 
Lex). 
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DISCUSSION 
 
  Lex is a glycan motif (glycan structure) known as an epitope that comprises SSEA-1 
and CD15. Fut9 is a key enzyme required for its synthesis that is thought to also bear on 
various life phenomena as it is expressed in a cell- and developmental stage-specific 
manner. To elucidate the function of the Lex, it is important to identify the proteins that 
carry it. Conventional techniques using antibodies have been used to identify Lex-carrier 
proteins. In the Western blotting of mouse kidney homogenates using the anti-SSEA-1 
antibody, we could observe only a few bands, indicating that the SSEA-1 antibody 
bound to selected glycoproteins among many of the potential Lex carriers. However, 
most of the complex-type N-glycans contained multiple fucoses (Figure 2a). This 
suggested that the anti-SSEA-1 antibody might recognize not simply Lex but also a 
portion of the proteins carrying Lex, or might have the potential for strong binding to 
Lex on only a specific subset of proteins. These results clearly suggest that Lex is an 
epitope indispensable for anti-SSEA-1 recognition, but it is not necessarily sufficient. 
  There have been some reports on successful identification of Lex-carriers using 
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existing techniques. For example, Liu identified 36 Lex-carrying glycoproteins from 
Namalwa cells (erythroid cells).29 However, in that study, because Fut9 was artificially 
overexpressed, the identification might not reflect physiological conditions. From the 
physiological expression of Lex in the native tissue, Hashii reported 10 glycoproteins in 
the mouse kidney as Lex carriers, such as megalin (low-density lipoprotein 
receptor-related protein 2), cubilin, and γ-GTP1 and 18 Lex-containing glycoforms. 
However, these glycoproteins were considered to be a small part of the glycoproteins 
having Lex. In our study, the profile of N-glycans released from total glycoproteins 
demonstrated that most of the complex-type N-glycans contained multiple fucoses, and 
we therefore supposed that Lex is carried on widespread proteins (Figure 2a).  
  As the comprehensive identification of Lex carrying proteins is quite difficult by the 
conventional method using antibody capturing, we designed a new approach that 
consisted of site-specific glycome analysis of glycopeptides enriched by HILIC 
followed by AAL affinity column to select glycopeptides having fucoses. 
Conventionally, it had been difficult to analyze site-specific glycome of glycopeptides 
without separating the glycan moiety from peptides. The previously developed 
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IGOT-LC–MS method20 is powerful and sensitive enough to identify deglycosylated 
peptides with information on the N-glycosylated site in a high-throughput manner. 
However, it cannot specify which glycan structure is attached to the glycosylated site. In 
this study, we developed a novel method for identifying the site-specific glycoforms on 
glycopeptides, on the basis of the information on peptide sequences (theoretical masses) 
provided by IGOT-LC–MS analysis (Figure 1). Software was developed to combine the 
results provided by the new method with the list of peptides provided by IGOT-LCMS. 
Another in-house software was also developed to select the glycopeptide signals as 
clusters.  
  Prior to the site-specific glycome analysis, we identified the profile of AAL(+) 
glycopeptides from WT and Fut9 KO mouse kidneys. In each strain, approximately 
2200 fucosylated-glycopeptides (800 fucosylated-glycoproteins) were identified, and 
66% (1800 peptides) overlapped between the WT and KO mice. Most of the 
complex-type N-glycans were fucosylated with multiple fucoses in WT (Figure 2a), 
which was also observed in the profile of the AAL(+) glycopeptides (Figure 3a). In 
contrast, all of the fucosylated-glycopeptides from the KO mice captured by AAL had a 
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single fucose that was predicted to represent a core fucose. This suggested that the 
glycoproteins having multiple fucoses in the WT mouse kidney contained terminal 
fucoses, which form the Lex structure, on a widespread variety of proteins. From the 
disappearance of terminal fucose consequent to knockout of Fut9 gene, it was 
confirmed that Lex is synthesized by Fut9. Furthermore, it could be speculated that 
almost all of the glycopeptides in AAL(+) fraction that overlapped between WT and 
KO mice carry Lex (66% of the total). 
  Thus, it became clear to us that Lex exists on a widespread spectrum of proteins 
rather than only on specific proteins in the mouse kidney. The glycopeptides contained 
in the AAL(+) fraction also include those carrying a core fucose alone without Lex. 
Although there were few of these, it was difficult to identify them in this study. 
Therefore, after performing a glycome comparison using site-specific glycome analysis, 
comprehensive Lex addition was observed in 81% of WT proteins, which disappeared in 
KO mice (Figure 6). These results supported the hypothesis that Lex is attached 
comprehensively to kidney glycoproteins. This finding is a new discovery that has not 
been reported elsewhere. Furthermore, because the terminal fucose competes with the 
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addition of sialic acid and inhibits sialylation, sialylated N-glycans were observed at 
very low levels in WT mice (Figure 3a). Accordingly, addition of Neu5Gc was 
enhanced after the disappearance of the terminal fucose facilitated by knockout of the 
Fut9 gene (Figure 3b), and there was no apparent alterations of the glycan structures 
other than sialylation. This strongly indicated that terminal fucosylation and sialylation 
in vivo are competitive for substrates. The terminal fucosylation, Lex, might play a role 
in keeping kidney cells in a neutral state by protecting against sialylation. This 
distinctive feature of Lex glycans might correlate with an essential function of the 
kidney, but additional studies will be necessary to address this question. 
  In this study, we used homogenates of whole kidney as our starting material. It has 
been reported that the glomeruli, which probably occupy less than 10% of the volume of 
the whole kidney, are highly sialylated.30-33 In WT kidney, glomeruli are strongly 
stained, whereas other areas are not stained by Sambucus nigra agglutinin (SNA) during 
lectin staining.34, 35 As shown in Figure 2a in this study, the percentage of sialylated 
N-glycans was very low. This might correlate with the low occupancy of glomeruli in 
the kidney. Additional glycome and glycoproteomics analysis using isolated glomeruli 
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will be necessary in the future to resolve this issue. 
  Most of the major complex-type N-glycans from the kidney contained Lewis-type 
fucose. In addition, we concluded that the terminal fucose in WT kidney was Lex 
because the Lewis type motif disappeared in the KO mice. From the site-specific 
glycome analysis of the WT sample, we were able to identify 51 glycosylated sites in 
WT mouse, which included 42 Lex-carrying glycosylation sites of 24 glycoproteins 
(Table 2). In our study, we reported 317 glycoforms from 24 Lex carrier proteins (Table 
2). Furthermore, most of the proteins identified from the AAL(+) IGOT were also 
expected to be Lex carriers. This shows the effectiveness of our glycan 
heterogeneity-based glycopeptide signal assignment method. By using the novel 
glycoproteomics technology described in this study, we were able to identify a larger 
number of Lex glycoprotein carriers in vivo as well as to confirm a greater variety of 
glycan structures. This is the first report of a large-scale identification of Lex-carrying 
glycoproteins. 
  In this study, we identified 2079 nonredundant AAL(+)-glycopeptides (Table 1, 
Supplementary Table 2) from both WT and KO mice by IGOT-LC–MS analyses as 
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candidates for the core peptides of glycopeptides; however, only 86 glycosylated sites 
were assigned by the site-specific glycome analysis by using new glycoproteomic 
technology (Supplementary Table 5). In general, the ionization efficiency of 
glycopeptides is significantly lower than that of nonglycosylated/deglycosylated 
peptides. Furthermore, the mass signals of glycopeptides having a common core peptide 
sequence but different glycans were dispersed due to the glycan heterogeneity. 
Therefore, the number of detectable glycopeptides was lower than anticipated. However, 
considering glycan variation on each glycopeptide, we could reveal 522 glycopeptide 
signals, 51 glycosylated sites in 24 glycoproteins (Table 2) in WT mice and 591 
glycopeptide signals, 70 glycosylated sites in 48 glycoproteins. These numbers are 
supposed to be the largest that have been reported so far. In the future, improvement of 
the detection coverage is one of the issues to be addressed. 
  In conclusion, many proteins in the kidney except for those in the glomeruli are likely 
to carry Lex. On the other hand, high sialylation has been observed in the glomerular 
glycan structures.36 Proximal tubules showed strong positive staining with both anti-Lex 
antibody and AAL.18 We plan to examine the tubular function in the kidney using the 
 33 
Fut9 KO mouse. Finally, the site-specific glycome analysis technology that was newly 
developed herein is applicable to other organs, cells, serum, and other systems. This 
technology might be a powerful tool for the elucidation of phenotypes of KO mice 
lacking specific carbohydrate epitopes, as well as for the discovery of new 
glyco-biomarkers of human disease. 
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TABLES 
 
Table 1. Identification of AAL(+) glycopeptides by the IGOT-LCMS method. 
 
Glycopeptides carrying fucosylated glycans were identified by the IGOT-LC–MS 
method followed by a Mascot search. The numbers of identified glycopeptides and 
glycoproteins of WT and KO mice are summarized. The numbers in parentheses are the 
number of nonredundant glycopeptide sequences. 
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Table 2. List of Lex-carrying proteins by site-specific glycome analysis. 
 
Le
x 
(+
)
pr
ot
ei
n
Pr
ot
ei
n
ac
ce
ss
io
n
Pr
ot
ei
n_
de
sc
rip
tio
n
Ex
pr
es
si
on
 a
nd
 lo
ca
liz
at
io
n

gi
|2
38
63
72
79
4F
2 
ce
ll-
su
rf
ac
e 
an
tig
en
 h
ea
vy
 c
ha
in
 is
of
or
m
 b
Th
e 
ba
so
la
te
ra
l m
em
br
an
e 
of
 k
id
ne
y 
pr
ox
im
al
 tu
bu
le
s 
an
d 
sm
al
l i
nt
es
tin
e 
ep
ith
el
ia
.

gi
|1
60
33
32
26
al
ka
lin
e 
ph
os
ph
at
as
e,
 ti
ss
ue
-n
on
sp
ec
ifi
c 
is
oz
ym
e 
pr
ec
ur
so
r
Ex
pr
es
se
d 
in
 li
ve
r/b
on
e/
ki
dn
ey
 (t
is
su
e-
no
ns
pe
ci
fic
).

gi
|4
65
59
38
9
an
gi
ot
en
si
n-
co
nv
er
tin
g 
en
zy
m
e 
is
of
or
m
 1
 p
re
cu
rs
or
gi
|3
34
68
87
3
an
gi
ot
en
si
n-
co
nv
er
tin
g 
en
zy
m
e 
is
of
or
m
 2
 p
re
cu
rs
or

gi
|2
10
14
75
89
be
ta
-1
,3
-g
al
ac
to
sy
l-O
-g
ly
co
sy
l-g
ly
co
pr
ot
ei
n 
be
ta
-1
,6
-N
-
ac
et
yl
gl
uc
os
am
in
yl
tr
an
sf
er
as
e
Ex
pr
es
se
d 
in
 p
ro
xi
m
al
 tu
bu
la
r c
yt
op
la
sm
ic
al
 c
el
ls
.

gi
|6
68
09
00
ca
dh
er
in
-1
6 
is
of
ro
m
 1
 p
re
cu
rs
or
gi
|3
57
93
36
52
ca
dh
er
in
-1
6 
is
of
or
m
 2
 p
re
cu
rs
or
gi
|3
57
93
36
54
ca
dh
er
in
-1
6 
is
of
or
m
 3
 p
re
cu
rs
or

gi
|6
75
34
84
co
lla
ge
n 
al
ph
a-
1(
VI
) c
ha
in
 p
re
cu
rs
or
B
as
em
en
t m
em
br
an
e.

gi
|1
24
48
73
48
cu
bi
lin
 p
re
cu
rs
or
gi
|1
24
48
73
48
cu
bi
lin
 p
re
cu
rs
or

gi
|1
61
01
68
33
di
pe
pt
id
as
e 
1 
pr
ec
ur
so
r
Ex
pr
es
se
d 
in
 a
pi
ca
l c
el
l m
em
br
an
e 
(r
en
al
 c
or
te
x 
> 
re
na
l m
ed
ul
la
 >
> 
re
na
l m
ed
ul
la


gi
|1
50
37
84
58
di
si
nt
eg
rin
 a
nd
 m
et
al
lo
pr
ot
ei
na
se
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 1
0
pr
ec
ur
so
r
O
ne
 o
f a
 s
he
dd
as
e 
(m
em
br
an
e-
bo
un
d 
en
zy
m
es
) a
nd
 e
xp
re
ss
ed
 in
 fe
ta
l b
ra
in
, l
iv
er
, h
ea
rt
,
ki
dn
ey
 a
nd
 lu
ng
, a
nd
 in
 ly
m
ph
oi
d 
tis
su
es
.

gi
|3
19
82
84
5
fo
la
te
 re
ce
pt
or
 a
lp
ha
 p
re
cu
rs
or
Ex
pr
es
se
d 
in
 d
is
ta
l r
en
al
 tu
bu
le
.

gi
|6
67
99
95
ga
m
m
a-
gl
ut
am
yl
tr
an
sp
ep
tid
as
e 
1 
pr
ec
ur
so
r
Lo
ca
te
d 
on
 th
e 
ou
te
r s
ur
fa
ce
 o
f t
he
 c
el
l m
em
br
an
e 
an
d 
w
id
el
y 
di
st
rib
ut
ed
 in
 m
am
m
al
ia
n
tis
su
es
  (
hi
gh
es
t e
xp
re
ss
io
n 
in
 th
e 
pr
ox
im
al
 tu
bu
le
 o
f t
he
 k
id
ne
y)
.

gi
|2
24
96
71
26
gr
an
ul
in
s 
pr
ec
ur
so
r
C
an
di
da
te
 g
ro
w
th
 fa
ct
or
s 
(h
ig
he
st
 le
ve
ls
 in
 k
id
ne
y)
.

gi
|4
55
04
39
4
in
te
gr
in
 b
et
a-
1 
pr
ec
ur
so
r
C
el
l a
dh
es
io
n 
m
ol
ec
ul
e.

gi
|1
24
48
73
72
lo
w
-d
en
si
ty
 li
po
pr
ot
ei
n 
re
ce
pt
or
-r
el
at
ed
 p
ro
te
in
 2
 p
re
cu
rs
or
Th
e 
ap
ic
al
 m
em
br
an
e 
do
m
ai
n 
of
 e
pi
th
el
ia
l c
el
ls
, i
nc
lu
di
ng
 p
ro
xi
m
al
 tu
bu
le
s.

gi
|3
19
82
19
9
m
ep
rin
 A
 s
ub
un
it 
al
ph
a

gi
|1
47
90
18
63
m
ep
rin
 A
 s
ub
un
it 
be
ta
 p
re
cu
rs
or

gi
|6
68
05
52
na
ps
in
-A
 p
re
cu
rs
or
A
n 
as
pa
rt
ic
 p
ro
te
as
e 
pr
es
en
t i
n 
th
e 
ep
ith
el
ia
l c
el
ls
 o
f t
he
 lu
ng
 a
nd
 k
id
ne
y.

gi
|3
15
43
25
5
ne
pr
ily
si
n
Ex
pr
es
se
d 
in
 p
od
oc
yt
es
, r
en
al
 p
ro
xi
m
al
 tu
bu
la
r e
pi
th
el
iu
m
.

gi
|8
29
98
93
1
PR
ED
IC
TE
D
: b
et
a-
1,
3-
ga
la
ct
os
yl
-O
-g
ly
co
sy
l-g
ly
co
pr
ot
ei
n 
be
ta
-
1,
6-
N
-a
ce
ty
lg
lu
co
sa
m
in
yl
tr
an
sf
er
as
e-
lik
e
Ex
pr
es
se
d 
in
 p
ro
xi
m
al
 tu
bu
la
r c
yt
op
la
sm
ic
al
 c
el
ls
.

gi
|6
75
31
38
so
di
um
/p
ot
as
si
um
-tr
an
sp
or
tin
g 
AT
Pa
se
 s
ub
un
it 
be
ta
-1
Th
e 
ac
tiv
e 
en
zy
m
e,
 w
hi
ch
 c
at
al
yz
es
 th
e 
hy
dr
ol
ys
is
 o
f A
TP
 c
ou
pl
ed
 w
ith
 th
e 
ex
ch
an
ge
 o
f
N
a(
+)
 a
nd
 K
(+
) i
on
s 
ac
ro
ss
 th
e 
pl
as
m
a 
m
em
br
an
e.

gi
|1
19
12
08
79
so
lu
te
 c
ar
rie
r f
am
ily
 3
, m
em
be
r 1
Ex
pr
es
se
d 
in
 c
yt
op
la
sm
ic
 a
nd
 m
em
br
an
e 
in
 tu
bu
le
s.

gi
|2
25
73
56
49
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 A
 p
re
pr
op
ro
te
in
gi
|2
25
73
56
45
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 B
 p
re
pr
op
ro
te
in
gi
|2
25
73
56
51
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 C
 p
re
pr
op
ro
te
in
gi
|2
25
73
56
53
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 D
 p
re
pr
op
ro
te
in
gi
|2
25
73
56
55
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 E
 p
re
pr
op
ro
te
in
gi
|2
25
73
56
57
su
lfa
te
d 
gl
yc
op
ro
te
in
 1
 is
of
or
m
 F
 p
re
pr
op
ro
te
in

gi
|2
51
82
38
24
su
sh
i d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 2
 is
of
or
m
 1
 p
re
cu
rs
or
gi
|2
51
82
38
26
su
sh
i d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 2
 is
of
or
m
 2
 p
re
cu
rs
or

gi
|2
27
49
94
99
tu
bu
lo
in
te
rs
tit
ia
l n
ep
hr
iti
s 
an
tig
en
 p
re
cu
rs
or
Ex
pr
es
se
d 
in
 p
ro
xi
m
al
 tu
bu
le
 a
nd
 in
te
rs
tit
iu
m
.

Lo
ca
liz
ed
 m
ai
nl
y 
to
 th
e 
ep
ith
el
ia
l c
el
ls
 o
f t
he
 d
is
ta
l r
en
al
 tu
bu
le
s 
or
 to
 th
e 
pa
rie
ta
l e
pi
th
el
ia
l
ce
lls
 o
f g
lo
m
er
ul
i.
Ex
pr
es
se
d 
in
 b
as
ol
at
er
al
 m
em
br
an
es
 o
f r
en
al
 tu
bu
la
r e
pi
th
el
ia
l c
el
ls
 .
Ex
pr
es
se
d 
in
 p
ro
xi
m
al
 tu
bu
le
 e
pi
th
el
ia
l c
el
ls
.
Ex
pr
es
se
d 
in
 a
pi
ca
l b
ru
sh
 b
or
de
rs
 o
f t
he
 p
ro
xi
m
al
 tu
bu
la
r e
pi
th
el
ia
l c
el
ls
.
Ex
pr
es
se
d 
in
 re
na
l p
ro
xi
m
al
 tu
bu
le
s.
Ex
pr
es
se
d 
in
 c
yt
op
la
sm
ic
 a
nd
 lu
m
in
al
 m
em
br
an
e 
in
 tu
bu
le
s.
 47 
FIGURE LEGENDS 
 
Figure 1. Procedure to identify glycoproteins carrying Lex in mouse kidney. To identify 
glycoproteins carrying Lex structures, first, glycopeptides having fucosylated glycans 
were enriched by AAL affinity chromatography from kidney homogenates of both WT 
and KO mice. Then (1) their core peptide sequences were identified by the IGOT-LC–
MS method and the glycan portions released from the glycopeptides (glycome) were 
analyzed by MALDI-MS; (2) To assign Lex carriers, the glycopeptide fractions were 
analyzed by LC–MS. Finally, using a set of three mass lists, the site-specific glycome 
was predicted using an in-house program. The cores of one or more members of each 
glycopeptide cluster were assigned by manual inspection of their respective MS/MS 
spectra. Lysyl endopeptidase (Lys C) 
 
Figure 2. Mass spectra of permethylated N-glycans released from whole (Amide(+)) 
glycopeptides of WT and KO mice. Mass spectra of the N-glycans released from 
Amide(+) glycopeptides of (a) WT and (b) KO mice are shown. The assigned glycan 
 48 
compositions are presented by digits (XYZ) indicating the numbers of Hex, HexNAc, 
and dHex monosaccharides, respectively, after elimination of the trimannosyl core 
(Hex3HexNAc2). In addition, two kinds of sialic acids, Neu5Ac and Neu5Gc, are 
indicated as Ac and Gc, respectively. On the basis of their compositions, most 
N-glycans were assigned as being high-mannose (gray) or fucosylated (black boxed) 
type. 
 
Figure 3. Mass spectra of permethylated N-glycans released from AAL(+) 
glycopeptides of WT and KO mice. Mass spectra of the N-glycans released from 
AAL(+) glycopeptides of (a) WT and (b) KO mice are shown. The assigned glycan 
compositions are presented by digits (XYZ), as indicated in Figure 2. Glycans having 
multiple fucoses suggesting the presence of Lex structures are indicated with black 
boxes.  
 
Figure 4. Comparisons of the MS/MS spectra of representative N-glycans. N-glycans 
released from the AAL(+) glycopeptides of WT and KO mice were permethylated and 
 49 
analyzed by MALDI-MS/MS. (a) Comparison of the MS/MS spectra between glycan 
precursors sharing Hex1HexNAc3 of WT (upper panel, signal 132 of Figure 3a) and 
KO (lower panel, inverted, signal 131 of Figure 3b) mice. (b) Comparison of the 
MS/MS spectra between glycan precursors sharing Hex2HexNAc3 of WT (upper panel, 
signal 233 of Figure 3a) and KO (lower panel, inverted, signal 231 of Figure 3b) mice. 
The masses of each precursor are shaded in gray. The hypothetical structures of 
precursors and fragment ions are shown around the signals. The fragments suggesting 
the presence of Lex are boxed. The glycans listed in this figure were assigned using the 
GlycoWorkBench software. 
 
Figure 5. Selection of glycopeptide signals as glycopeptide clusters using an in-house 
program. The AAL(+) glycopeptides were analyzed by a data-dependent LC–MS/MS 
method: MS was measured by Orbitrap analyzer. All MS signals (intensity >50000) are 
plotted (with gray squares) (WT: (a), KO: (c)) along with the retention time. Among 
them, the highest monoisotopic signals of each ion are shown in red. (b), (d) 
Glycopeptide signals were selected as clusters based on the conditions described in the 
 50 
Methods by in-house program. Each cluster is shown by verticallyconnected symbol. 
  
Figure 6. Detection and core assignment of glycopeptide clusters and identification of 
glycosylation sites and glycoproteins carrying Lex. (a)Using the in-house program, 103 
and 141 glycopeptide clusters were detected for WT and KO mice, respectively. Among 
them, for 72 (WT) and 99 (KO) clusters, their core peptides were confirmed by MS/MS 
spectrum inspection. (b) Identification of Lex-carrying glycopeptides by site-specific 
glycome analysis. For WT, 72 clusters correspond to 51 glycosylated sites, and 42 
(=14+28) sites included Lex-containing glycopeptides; for KO, 99 clusters correspond 
to 70 sites and all but one sites did not contain Lex-containing glycopeptide. (c) 
Identification of Lex-carrying glycoproteins. For WT, 51 sites correspond to 32 
glycoproteins, and 24 (= 3 + 21) were Lex-carrying proteins.  
 
Figure 7. Comparison of the site-specific N-glycomes of a representative glycosylated 
site (Asn-489 in cadherin-16) found in both WT and KO mice. The number of 
monosaccharides (glycan compositions) after eliminating the trimannosyl core is listed. 
 51 
The presence or absence of the glycan structures at each site in WT and KO mice are 
indicated with a “+” or “-“, respectively. The symbol (+) including multiple fucoses in 
WT mice are indicated in gray. Presumed glycan structures having maximum 
fucosylation in the same glycan skeleton, e.g., Hex1HexNAc3 (dHex1 or 3), are shown 
in the right columns.  
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Supporting Information 
The Supporting Information is attached to CD-R. 
 
List of masses (m/z) of glycopeptides captured by Amide 80 column; list of AAL(+) 
glycopeptides identified by Mascot search; list of masses (m/z) of glycopeptides 
captured by AAL column; list of mass values of representative fragment ions of 
glycans; list of Lex-carrying proteins by site-specific glycome analysis; representative 
MS/MS spectra of glycopeptides to confirm their core peptides and glycan composition 
(PDF) 
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